{"id":21014,"date":"2021-07-28T18:49:15","date_gmt":"2021-07-28T22:49:15","guid":{"rendered":"https:\/\/www.cosprc.ca\/?p=21014"},"modified":"2021-07-28T18:54:53","modified_gmt":"2021-07-28T22:54:53","slug":"guidelines-for-supply-triage-during-visudyne-verteporfin-shortage","status":"publish","type":"post","link":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/","title":{"rendered":"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage"},"content":{"rendered":"\n<p><strong>Lignes directrices pour l\u2019attribution de l\u2019approvisionnement restant durant la<\/strong><strong>&nbsp;<\/strong><strong>p\u00e9nurie de<\/strong><strong>&nbsp;<\/strong><strong>Visudyne (vert\u00e9porfine)<\/strong><\/p>\n\n\n\n<p><em>Le 16&nbsp;juillet&nbsp;2021<\/em><\/p>\n\n\n\n<p>La Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies r\u00e9tiniennes et choro\u00efdiennes qui menacent la vue, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire n\u00e9ovasculaire li\u00e9e \u00e0 l\u2019\u00e2ge (nDMLA) r\u00e9sistante aux anti-VEGF et la chorior\u00e9tinopathie s\u00e9reuse centrale (CRSC). Il y a actuellement une p\u00e9nurie mondiale de Visudyne, et on pr\u00e9voit que le prochain r\u00e9approvisionnement n\u2019arrivera pas au Canada avant la&nbsp;fin de janvier&nbsp;2022 (voir <a href=\"https:\/\/www.penuriesdemedicamentscanada.ca\/shortage\/123386\">www.penuriesdemedicamentscanada.ca<\/a>).<\/p>\n\n\n\n<p>La Soci\u00e9t\u00e9 canadienne de la r\u00e9tine (SCR) et la Soci\u00e9t\u00e9 canadienne d\u2019ophtalmologie (SCO) collaborent avec l\u2019Unit\u00e9 des p\u00e9nuries de m\u00e9dicaments de Sant\u00e9 Canada dans ce dossier. De&nbsp;plus, la SCR et la SCO proposent l\u2019adoption d\u2019une strat\u00e9gie d\u2019att\u00e9nuation consistant \u00e0 attribuer l\u2019approvisionnement restant de Visudyne selon les priorit\u00e9s suivantes&nbsp;:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Priorit\u00e9 1&nbsp;: Traitement complet et prise en charge des tumeurs oculaires qui menacent la&nbsp;vue<\/li><li>Priorit\u00e9 2&nbsp;: Traitement de la CRSC non r\u00e9solue<\/li><li>Priorit\u00e9 3&nbsp;: Traitement de la nDMLA r\u00e9sistante aux anti\u2011VEGF<\/li><\/ul>\n\n\n\n<p>La SCR et la SCO fournissent ces renseignements \u00e0 des fins d\u2019orientation et exhortent tous les ophtalmologistes traitants \u00e0 collaborer avec leurs groupes locaux et r\u00e9gionaux de sp\u00e9cialistes en oncologie et en r\u00e9tine afin d\u2019assurer l\u2019attribution r\u00e9fl\u00e9chie de cet agent aux patients qui en ont le plus besoin.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lignes directrices pour l\u2019attribution de l\u2019approvisionnement restant durant la&nbsp;p\u00e9nurie de&nbsp;Visudyne (vert\u00e9porfine) Le 16&nbsp;juillet&nbsp;2021 La Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies r\u00e9tiniennes et choro\u00efdiennes qui menacent la vue, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire n\u00e9ovasculaire li\u00e9e \u00e0 l\u2019\u00e2ge (nDMLA) r\u00e9sistante aux anti-VEGF et la chorior\u00e9tinopathie s\u00e9reuse centrale (CRSC). [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[305],"post_tag":[],"content_type":[326],"class_list":["post-21014","post","type-post","status-publish","format-standard","hentry","category-pour-les-ophtalmologistes","content_type-enonce-de-principes-et-lignes-directrices"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage - Practice Resource Centre<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage - Practice Resource Centre\" \/>\n<meta property=\"og:description\" content=\"Lignes directrices pour l\u2019attribution de l\u2019approvisionnement restant durant la&nbsp;p\u00e9nurie de&nbsp;Visudyne (vert\u00e9porfine) Le 16&nbsp;juillet&nbsp;2021 La Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies r\u00e9tiniennes et choro\u00efdiennes qui menacent la vue, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire n\u00e9ovasculaire li\u00e9e \u00e0 l\u2019\u00e2ge (nDMLA) r\u00e9sistante aux anti-VEGF et la chorior\u00e9tinopathie s\u00e9reuse centrale (CRSC). [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/\" \/>\n<meta property=\"og:site_name\" content=\"Practice Resource Centre\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-28T22:49:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-28T22:54:53+00:00\" \/>\n<meta name=\"author\" content=\"Fetun Delessa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fetun Delessa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/\"},\"author\":{\"name\":\"Fetun Delessa\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/3fca208dd4d156beb92f181ee1629eb1\"},\"headline\":\"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage\",\"datePublished\":\"2021-07-28T22:49:15+00:00\",\"dateModified\":\"2021-07-28T22:54:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/\"},\"wordCount\":274,\"articleSection\":[\"Pour les ophtalmologistes\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/\",\"name\":\"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage - Practice Resource Centre\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\"},\"datePublished\":\"2021-07-28T22:49:15+00:00\",\"dateModified\":\"2021-07-28T22:54:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/3fca208dd4d156beb92f181ee1629eb1\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/\",\"name\":\"Practice Resource Centre\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cosprc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/3fca208dd4d156beb92f181ee1629eb1\",\"name\":\"Fetun Delessa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g\",\"caption\":\"Fetun Delessa\"},\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/author\\\/rs9ebny670cpwyyn\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage - Practice Resource Centre","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/","og_locale":"fr_FR","og_type":"article","og_title":"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage - Practice Resource Centre","og_description":"Lignes directrices pour l\u2019attribution de l\u2019approvisionnement restant durant la&nbsp;p\u00e9nurie de&nbsp;Visudyne (vert\u00e9porfine) Le 16&nbsp;juillet&nbsp;2021 La Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies r\u00e9tiniennes et choro\u00efdiennes qui menacent la vue, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire n\u00e9ovasculaire li\u00e9e \u00e0 l\u2019\u00e2ge (nDMLA) r\u00e9sistante aux anti-VEGF et la chorior\u00e9tinopathie s\u00e9reuse centrale (CRSC). [&hellip;]","og_url":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/","og_site_name":"Practice Resource Centre","article_published_time":"2021-07-28T22:49:15+00:00","article_modified_time":"2021-07-28T22:54:53+00:00","author":"Fetun Delessa","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Fetun Delessa","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/#article","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/"},"author":{"name":"Fetun Delessa","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/3fca208dd4d156beb92f181ee1629eb1"},"headline":"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage","datePublished":"2021-07-28T22:49:15+00:00","dateModified":"2021-07-28T22:54:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/"},"wordCount":274,"articleSection":["Pour les ophtalmologistes"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/","url":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/","name":"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage - Practice Resource Centre","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/#website"},"datePublished":"2021-07-28T22:49:15+00:00","dateModified":"2021-07-28T22:54:53+00:00","author":{"@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/3fca208dd4d156beb92f181ee1629eb1"},"breadcrumb":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cosprc.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Guidelines for Supply Triage During Visudyne (Verteporfin) Shortage"}]},{"@type":"WebSite","@id":"https:\/\/www.cosprc.ca\/#website","url":"https:\/\/www.cosprc.ca\/","name":"Practice Resource Centre","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cosprc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/3fca208dd4d156beb92f181ee1629eb1","name":"Fetun Delessa","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a10a9c4e762ba75e5efa9baf63e485c514bcd87a33ad1c13fc83f941e4ef0034?s=96&d=mm&r=g","caption":"Fetun Delessa"},"url":"https:\/\/www.cosprc.ca\/fr\/author\/rs9ebny670cpwyyn\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-29 18:41:29","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/21014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/comments?post=21014"}],"version-history":[{"count":2,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/21014\/revisions"}],"predecessor-version":[{"id":21016,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/21014\/revisions\/21016"}],"wp:attachment":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/media?parent=21014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/categories?post=21014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/post_tag?post=21014"},{"taxonomy":"content_type","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/content_type?post=21014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}